Highly Efficient Monophosphine-Based Catalyst for the Palladium-Catalyzed Suzuki−Miyaura Reaction of Heteroaryl Halides and Heteroaryl Boronic Acids and Esters
作者:Kelvin Billingsley、Stephen L. Buchwald
DOI:10.1021/ja068577p
日期:2007.3.1
active and efficient catalyst system derived from a palladium precatalyst and monophosphine ligands 1 or 2 for the Suzuki-Miyaura cross-coupling reaction of heteroaryl boronic acids and esters has been developed. This method allows for the preparation of a wide variety of heterobiaryls in good to excellent yields and displays a high level of activity for the coupling of heteroaryl chlorides as well as
2‐Sulfonylpyrimidines were identified to inhibit the enzymatic activity of the kinesinHSET by covalently targetingcysteine residues and to induce multipolar mitoses and oxidative stress, thus emphasizing the pleiotropic effects of these alkylating agents in cells.
Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases
作者:Ulrike E. Hille、Christina Zimmer、Jörg Haupenthal、Rolf W. Hartmann
DOI:10.1021/ml100283h
日期:2011.8.11
CYP11B1 is the key enzyme in cortisol biosynthesis, and its inhibition with selective compounds is a promising strategy for the treatment of diseases associated with elevated cortisol levels, such as Cushing’s syndrome or metabolic disease. Expanding on a previous study from our group resulting in the first potent and rather selectiveinhibitor described so far (1, IC50 = 152 nM), we herein describe
CYP11B1 是皮质醇生物合成的关键酶,它用选择性化合物抑制是治疗与皮质醇水平升高相关的疾病(如库欣综合征或代谢疾病)的有前景的策略。Expanding on a previous study from our group resulting in the first potent and rather selective inhibitor described so far ( 1 , IC 50 = 152 nM), we herein describe further optimizations of the imidazolylmethyl pyridine core. 合成的 42 种物质中有五种化合物的 IC 50值低于 50 nM。最有趣的是naphth-1-yl 化合物23 (IC 50 = 42 nM),对高度同源的CYP11B2 ( 1:18 倍)以及分别对雄激素和雌激素形成酶
Hypoglycemic imidazoline compounds
申请人:ELI LILLY AND COMPANY
公开号:EP1266897A3
公开(公告)日:2003-12-03
This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.The compounds have the following formula: whereinX is -O-, -S-, or -NR5-;R5 is hydrogen, C1-8 alkyl, or an amino protecting group;R4 isY is -O-, -S-, or -NR8-;Y' is -O- or -S-;